Home
Conditions
Neoplasm, Residual

Clinical trial condition

Neoplasm, Residual

Explore clinical trials studying Neoplasm, Residual. Study availability and eligibility vary by location and protocol.

207 public trials 79 recruiting studies

Refine in advanced search Browse all conditions

Neoplasm, Residual trial results

Active, not recruiting

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT02159495

Conditions: Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Adult Acute Lymphoblastic Leukemia, +35 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Active, not recruiting

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

NCT03876769

Conditions: B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +19 more
Locations: Children s Hospital of Alabama Birmingham, Alabama, United States

Phoenix Childrens Hospital Phoenix, Arizona, United States

City of Hope National Medical Duarte, California, United States

Childrens Hospital Los Angeles Los Angeles, California, United States

View all 43 locations

View Trial Details

Active, not recruiting

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

NCT00923013

Conditions: Hairy Cell Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +12 more
Locations: National Institutes of Health Clinical Center Bethesda, Maryland, United States

View Trial Details

Active, not recruiting

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

NCT07136077

Conditions: Adjuvant Chemotherapy, Colonic Diseases, Colorectal Cancer, +18 more
Locations: MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, not recruiting

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

NCT06358430

Conditions: Colonic Diseases, Colorectal Cancer, Colorectal Neoplasms, +14 more
Locations: MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, not recruiting

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

NCT01059786

Conditions: Hairy Cell Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +12 more
Locations: National Institutes of Health Clinical Center Bethesda, Maryland, United States

View Trial Details

Active, not recruiting

Elimination of Minimal Residual Disease After Transplant

NCT05690984

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations: Froedtert Hospital & the Medical College of Wisconsin Milwaukee, Wisconsin, United States

View Trial Details

Active, not recruiting

Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies

NCT03241940

Conditions: B Acute Lymphoblastic Leukemia, Burkitt Lymphoma, CD19 Positive, +29 more
Locations: Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States

View Trial Details

Active, not recruiting

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia

NCT02724163

Conditions: Acute Myeloid Leukaemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations: Women and Children's Hospital Adelaide Adelaide, Australia

Queensland Children's Hospital Brisbane, Australia

Monash Children's Hospital Melbourne, Australia

Royal Childrens Hospital Melbourne, Australia

View all 68 locations

View Trial Details

Active, not recruiting

A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients

NCT03945721

Conditions: Breast Diseases, Breast Neoplasms, Neoplasm, Residual, +10 more
Locations: Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States

Dana Farber Cancer Institute/Brigham and Women's Hospital Boston, Massachusetts, United States

View Trial Details

Neoplasm, Residual

Neoplasm, Residual trial results

Related conditions